Literature DB >> 22736087

The burden of carotid artery plaques is higher in patients with psoriatic arthritis compared with those with psoriasis alone.

Lihi Eder1, Jai Jayakar, Sutha Shanmugarajah, Arane Thavaneswaran, Daniel Pereira, Vinod Chandran, Cheryl F Rosen, Dafna D Gladman.   

Abstract

AIM: To compare the extent of atherosclerosis in patients with psoriatic arthritis (PsA) and patients with cutaneous psoriasis without arthritis (PsC).
METHODS: In this cross-sectional study the authors compared patients with PsA with PsC patients. Psoriasis patients underwent a rheumatological assessment to exclude inflammatory arthritis. Ultrasonographic measurements of carotid total plaque area (TPA) and carotid intima-media thickness (cIMT) were performed. t Test was used to compare the imaging findings between the two groups. Multivariate linear regression analysis was used to assess the association between disease status and imaging findings after adjusting for potential confounders.
RESULTS: Overall, 125 PsA and 114 PsC patients were compared. There were no significant differences in age, gender or cardiovascular risk factors between the two groups. Patients with PsA exhibited greater TPA than did PsC patients (TPA (square root of area in mm(2)) 3.33±3.34 vs 2.43±2.72, p=0.03). This difference remained statistically significant in the multivariate regression analysis after adjusting for potential confounders (p=0.03). The difference in cIMT between the groups did not achieve statistical significance (p=0.09). The following disease-related variables were associated with increase in TPA in multivariate regression analysis among PsA patients: duration of PsA (p=0.04), highest Psoriasis Area and Severity Index recorded in the first 3 years of follow-up (p=0.02) and erythrocyte sedimentation rate (p=0.005).
CONCLUSIONS: PsA patients suffer from more severe subclinical atherosclerosis compared with patients with PsC. This difference is independent of traditional cardiovascular risk factors and correlates with PsA disease duration, more severe skin disease and increased inflammatory markers.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22736087     DOI: 10.1136/annrheumdis-2012-201497

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  21 in total

1.  Investigation of subclinical atherosclerosis in psoriatic arthritis patients with minimal disease activity.

Authors:  Baris Yilmazer; Tayfun Sahin; Berrin Öztaş Unlu; Hale Maral Kir; Ayse Cefle
Journal:  Rheumatol Int       Date:  2015-02-11       Impact factor: 2.631

2.  Feasibility of carotid artery PET/MRI in psoriasis patients.

Authors:  Prabhakar Rajiah; Mojgan Hojjati; Ziang Lu; Vijaya Kosaraju; Sasan Partovi; James K O'Donnell; Christopher Longenecker; Grace A McComsey; Jackelyn B Golden; Fuad Muakkassa; Scott Santilli; Thomas S McCormick; Kevin D Cooper; Neil J Korman
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-08-20

Review 3.  Cardiometabolic Disorders in Psoriatic Disease.

Authors:  Curtis Sobchak; Lihi Eder
Journal:  Curr Rheumatol Rep       Date:  2017-08-26       Impact factor: 4.592

4.  Identification and management of comorbidity in psoriatic arthritis: evidence- and expert-based recommendations from a multidisciplinary panel from Spain.

Authors:  Juan Carlos Torre-Alonso; Loreto Carmona; Mireia Moreno; Eva Galíndez; Jesús Babío; Pedro Zarco; Luis Linares; Eduardo Collantes-Estevez; Manuel Fernández Barrial; Juan Carlos Hermosa; Pablo Coto; Carmen Suárez; Raquel Almodóvar; Jesús Luelmo; Santos Castañeda; Jordi Gratacós
Journal:  Rheumatol Int       Date:  2017-04-07       Impact factor: 2.631

Review 5.  Chronic inflammation, cardiometabolic diseases and effects of treatment: Psoriasis as a human model.

Authors:  Milena Aksentijevich; Sundus S Lateef; Paula Anzenberg; Amit K Dey; Nehal N Mehta
Journal:  Trends Cardiovasc Med       Date:  2019-11-20       Impact factor: 6.677

Review 6.  Updates on cardiovascular comorbidities associated with psoriatic diseases: epidemiology and mechanisms.

Authors:  Kaitlyn M Yim; April W Armstrong
Journal:  Rheumatol Int       Date:  2016-05-24       Impact factor: 2.631

7.  Gaps in Diagnosis and Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease: An International Multicenter Study.

Authors:  Lihi Eder; Paula Harvey; Vinod Chandran; Cheryl F Rosen; Jan Dutz; James T Elder; Proton Rahman; Christopher T Ritchlin; Sherry Rohekar; Richard Hayday; Snezana Barac; Joy Feld; Devy Zisman; Dafna D Gladman
Journal:  J Rheumatol       Date:  2018-02-01       Impact factor: 4.666

Review 8.  Cardiovascular Risk in Patients With Psoriasis: JACC Review Topic of the Week.

Authors:  Michael S Garshick; Nicole L Ward; James G Krueger; Jeffrey S Berger
Journal:  J Am Coll Cardiol       Date:  2021-04-06       Impact factor: 24.094

Review 9.  New Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies.

Authors:  Di Yan; Andrew Blauvelt; Amit K Dey; Rachel S Golpanian; Samuel T Hwang; Nehal N Mehta; Bridget Myers; Zhen-Rui Shi; Gil Yosipovitch; Stacie Bell; Wilson Liao
Journal:  J Invest Dermatol       Date:  2021-04-19       Impact factor: 7.590

Review 10.  Clinical, laboratory, and genetic markers for the development or presence of psoriatic arthritis in psoriasis patients: a systematic review.

Authors:  Michelle L M Mulder; Tamara W van Hal; Mark H Wenink; Hans J P M Koenen; Frank H J van den Hoogen; Elke M G J de Jong; Juul M P A van den Reek; Johanna E Vriezekolk
Journal:  Arthritis Res Ther       Date:  2021-06-14       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.